TrimTabs Asset Management LLC grew its position in Colgate-Palmolive (NYSE:CL) by 24.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,569 shares of the company’s stock after purchasing an additional 4,811 shares during the period. Colgate-Palmolive comprises about 1.0% of TrimTabs Asset Management LLC’s holdings, making the stock its 29th largest position. TrimTabs Asset Management LLC’s holdings in Colgate-Palmolive were worth $1,946,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in Colgate-Palmolive in the 4th quarter worth about $25,000. Advisory Alpha LLC acquired a new position in shares of Colgate-Palmolive during the 3rd quarter valued at about $28,000. Grant Street Asset Management Inc. acquired a new position in shares of Colgate-Palmolive during the 4th quarter valued at about $28,000. TRU Independence Asset Management 2 LLC acquired a new position in shares of Colgate-Palmolive during the 4th quarter valued at about $29,000. Finally, Encompass Wealth Advisors LLC acquired a new position in shares of Colgate-Palmolive during the 4th quarter valued at about $29,000. 76.47% of the stock is currently owned by institutional investors.
In other news, insider Jennifer Daniels sold 20,692 shares of the firm’s stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $78.65, for a total value of $1,627,425.80. Following the transaction, the insider now directly owns 55,585 shares in the company, valued at approximately $4,371,760.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Patricia Verduin sold 1,513 shares of the firm’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $77.16, for a total value of $116,743.08. Following the completion of the transaction, the chief technology officer now owns 45,545 shares in the company, valued at $3,514,252.20. The disclosure for this sale can be found here. Insiders sold a total of 30,810 shares of company stock valued at $2,418,650 over the last three months. Insiders own 0.78% of the company’s stock.
Shares of NYSE CL traded down $0.29 during midday trading on Thursday, hitting $79.33. The stock had a trading volume of 130,305 shares, compared to its average volume of 5,030,974. The company’s 50-day simple moving average is $76.89 and its 200 day simple moving average is $80.38. The firm has a market cap of $67.23 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 3.83 and a beta of 0.59. Colgate-Palmolive has a fifty-two week low of $65.54 and a fifty-two week high of $86.41. The company has a debt-to-equity ratio of 6.50, a current ratio of 0.97 and a quick ratio of 0.62.
Colgate-Palmolive (NYSE:CL) last released its earnings results on Thursday, January 28th. The company reported $0.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.01. The company had revenue of $4.32 billion during the quarter, compared to analysts’ expectations of $4.15 billion. Colgate-Palmolive had a return on equity of 383.88% and a net margin of 16.65%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm earned $0.73 EPS. Equities analysts expect that Colgate-Palmolive will post 3.05 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, May 14th. Stockholders of record on Wednesday, April 21st will be paid a $0.45 dividend. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.44. This represents a $1.80 annualized dividend and a dividend yield of 2.27%. The ex-dividend date is Tuesday, April 20th. Colgate-Palmolive’s dividend payout ratio (DPR) is 62.19%.
A number of brokerages have commented on CL. Credit Suisse Group upgraded Colgate-Palmolive from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $70.00 to $80.00 in a research report on Monday, February 1st. Stifel Nicolaus downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating and set a $83.00 price objective for the company. in a research report on Thursday, January 28th. Berenberg Bank upgraded Colgate-Palmolive from a “sell” rating to a “hold” rating and set a $76.00 price objective for the company in a research report on Tuesday, January 26th. Sanford C. Bernstein started coverage on Colgate-Palmolive in a research report on Tuesday, January 19th. They issued an “underperform” rating and a $77.00 price objective for the company. Finally, Royal Bank of Canada cut Colgate-Palmolive from an “outperform” rating to a “sector perform” rating and set a $90.00 target price for the company. in a report on Monday, January 4th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $81.91.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment's products include toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other similar items.
Further Reading: What does earnings per share mean?
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.